Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. / Schäfer, S A; Tschritter, O; Machicao, F; Thamer, C; Stefan, N; Gallwitz, B; Holst, Jens Juul; Dekker, J M; 't Hart, L M; t'Hart, L M; Nijpels, G; van Haeften, T W; Häring, H U; Fritsche, A.

In: Diabetologia, Vol. 50, No. 12, 12.2007, p. 2443-50.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Schäfer, SA, Tschritter, O, Machicao, F, Thamer, C, Stefan, N, Gallwitz, B, Holst, JJ, Dekker, JM, 't Hart, LM, t'Hart, LM, Nijpels, G, van Haeften, TW, Häring, HU & Fritsche, A 2007, 'Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms', Diabetologia, vol. 50, no. 12, pp. 2443-50. https://doi.org/10.1007/s00125-007-0753-6

APA

Schäfer, S. A., Tschritter, O., Machicao, F., Thamer, C., Stefan, N., Gallwitz, B., ... Fritsche, A. (2007). Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia, 50(12), 2443-50. https://doi.org/10.1007/s00125-007-0753-6

Vancouver

Schäfer SA, Tschritter O, Machicao F, Thamer C, Stefan N, Gallwitz B et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia. 2007 Dec;50(12):2443-50. https://doi.org/10.1007/s00125-007-0753-6

Author

Schäfer, S A ; Tschritter, O ; Machicao, F ; Thamer, C ; Stefan, N ; Gallwitz, B ; Holst, Jens Juul ; Dekker, J M ; 't Hart, L M ; t'Hart, L M ; Nijpels, G ; van Haeften, T W ; Häring, H U ; Fritsche, A. / Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. In: Diabetologia. 2007 ; Vol. 50, No. 12. pp. 2443-50.

Bibtex

@article{f51ab49b2aa44a179fed45c8484d3824,
title = "Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms",
abstract = "AIMS/HYPOTHESIS: Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes and reduced insulin secretion. The transcription factor TCF7L2 is an essential factor for glucagon-like peptide-1 (GLP-1) secretion from intestinal L cells. We studied whether a defect in the enteroinsular axis contributes to impaired insulin secretion in carriers of TCF7L2 polymorphisms.METHODS: We genotyped 1,110 non-diabetic German participants for five single nucleotide polymorphisms in TCF7L2. All participants underwent an OGTT; GLP-1 secretion was measured in 155 participants. In 210 participants, an IVGTT combined with a hyperinsulinaemic-euglycaemic clamp was performed. In another 160 participants from the Netherlands and 73 from Germany, a hyperglycaemic clamp (10 mmol/l) was performed. In 73 German participants this clamp was combined with a GLP-1 infusion and an arginine bolus.RESULTS: The OGTT data confirmed that variants in TCF7L2 are associated with reduced insulin secretion. In contrast, insulin secretion induced by an i.v. glucose challenge in the IVGTT and hyperglycaemic clamp was not different between the genotypes. GLP-1 concentrations during the OGTT were not influenced by the TCF7L2 variants. However, GLP-1-infusion combined with a hyperglycaemic clamp showed a significant reduction in GLP-1-induced insulin secretion in carriers of the risk allele in two variants (rs7903146, rs12255372, p < 0.02).CONCLUSIONS/INTERPRETATION: Variants of TCF7L2 specifically impair GLP-1-induced insulin secretion. This seems to be rather the result of a functional defect in the GLP-1 signalling in beta cells than a reduction in GLP-1 secretion. This defect might explain the impaired insulin secretion in carriers of the risk alleles and confers the increased risk of type 2 diabetes.",
keywords = "Adult, Arginine, Blood Glucose, Female, Glucagon-Like Peptide 1, Glucose Clamp Technique, Glucose Intolerance, Glucose Tolerance Test, Heterozygote, Humans, Insulin, Insulin Resistance, Male, Middle Aged, Polymorphism, Single Nucleotide, TCF Transcription Factors, Transcription Factor 7-Like 2 Protein",
author = "Sch{\"a}fer, {S A} and O Tschritter and F Machicao and C Thamer and N Stefan and B Gallwitz and Holst, {Jens Juul} and Dekker, {J M} and {'t Hart}, {L M} and t'Hart, {L M} and G Nijpels and {van Haeften}, {T W} and H{\"a}ring, {H U} and A Fritsche",
year = "2007",
month = "12",
doi = "10.1007/s00125-007-0753-6",
language = "English",
volume = "50",
pages = "2443--50",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms

AU - Schäfer, S A

AU - Tschritter, O

AU - Machicao, F

AU - Thamer, C

AU - Stefan, N

AU - Gallwitz, B

AU - Holst, Jens Juul

AU - Dekker, J M

AU - 't Hart, L M

AU - t'Hart, L M

AU - Nijpels, G

AU - van Haeften, T W

AU - Häring, H U

AU - Fritsche, A

PY - 2007/12

Y1 - 2007/12

N2 - AIMS/HYPOTHESIS: Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes and reduced insulin secretion. The transcription factor TCF7L2 is an essential factor for glucagon-like peptide-1 (GLP-1) secretion from intestinal L cells. We studied whether a defect in the enteroinsular axis contributes to impaired insulin secretion in carriers of TCF7L2 polymorphisms.METHODS: We genotyped 1,110 non-diabetic German participants for five single nucleotide polymorphisms in TCF7L2. All participants underwent an OGTT; GLP-1 secretion was measured in 155 participants. In 210 participants, an IVGTT combined with a hyperinsulinaemic-euglycaemic clamp was performed. In another 160 participants from the Netherlands and 73 from Germany, a hyperglycaemic clamp (10 mmol/l) was performed. In 73 German participants this clamp was combined with a GLP-1 infusion and an arginine bolus.RESULTS: The OGTT data confirmed that variants in TCF7L2 are associated with reduced insulin secretion. In contrast, insulin secretion induced by an i.v. glucose challenge in the IVGTT and hyperglycaemic clamp was not different between the genotypes. GLP-1 concentrations during the OGTT were not influenced by the TCF7L2 variants. However, GLP-1-infusion combined with a hyperglycaemic clamp showed a significant reduction in GLP-1-induced insulin secretion in carriers of the risk allele in two variants (rs7903146, rs12255372, p < 0.02).CONCLUSIONS/INTERPRETATION: Variants of TCF7L2 specifically impair GLP-1-induced insulin secretion. This seems to be rather the result of a functional defect in the GLP-1 signalling in beta cells than a reduction in GLP-1 secretion. This defect might explain the impaired insulin secretion in carriers of the risk alleles and confers the increased risk of type 2 diabetes.

AB - AIMS/HYPOTHESIS: Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes and reduced insulin secretion. The transcription factor TCF7L2 is an essential factor for glucagon-like peptide-1 (GLP-1) secretion from intestinal L cells. We studied whether a defect in the enteroinsular axis contributes to impaired insulin secretion in carriers of TCF7L2 polymorphisms.METHODS: We genotyped 1,110 non-diabetic German participants for five single nucleotide polymorphisms in TCF7L2. All participants underwent an OGTT; GLP-1 secretion was measured in 155 participants. In 210 participants, an IVGTT combined with a hyperinsulinaemic-euglycaemic clamp was performed. In another 160 participants from the Netherlands and 73 from Germany, a hyperglycaemic clamp (10 mmol/l) was performed. In 73 German participants this clamp was combined with a GLP-1 infusion and an arginine bolus.RESULTS: The OGTT data confirmed that variants in TCF7L2 are associated with reduced insulin secretion. In contrast, insulin secretion induced by an i.v. glucose challenge in the IVGTT and hyperglycaemic clamp was not different between the genotypes. GLP-1 concentrations during the OGTT were not influenced by the TCF7L2 variants. However, GLP-1-infusion combined with a hyperglycaemic clamp showed a significant reduction in GLP-1-induced insulin secretion in carriers of the risk allele in two variants (rs7903146, rs12255372, p < 0.02).CONCLUSIONS/INTERPRETATION: Variants of TCF7L2 specifically impair GLP-1-induced insulin secretion. This seems to be rather the result of a functional defect in the GLP-1 signalling in beta cells than a reduction in GLP-1 secretion. This defect might explain the impaired insulin secretion in carriers of the risk alleles and confers the increased risk of type 2 diabetes.

KW - Adult

KW - Arginine

KW - Blood Glucose

KW - Female

KW - Glucagon-Like Peptide 1

KW - Glucose Clamp Technique

KW - Glucose Intolerance

KW - Glucose Tolerance Test

KW - Heterozygote

KW - Humans

KW - Insulin

KW - Insulin Resistance

KW - Male

KW - Middle Aged

KW - Polymorphism, Single Nucleotide

KW - TCF Transcription Factors

KW - Transcription Factor 7-Like 2 Protein

U2 - 10.1007/s00125-007-0753-6

DO - 10.1007/s00125-007-0753-6

M3 - Journal article

VL - 50

SP - 2443

EP - 2450

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 12

ER -

ID: 132049933